Epigen Intimate spray 0.1%, 15ml

treatment of viral infection caused by the human papillomavirus, incl. asymptomatic isolation of human papillomavirus of high oncogenic risk, as part of combination and complex therapy;

treatment of a viral infection caused by the herpes simplex virus types 1 and 2 as part of complex therapy;

treatment of a viral infection caused by the Varicella Zoster virus (shingles) as part of complex therapy;

treatment of viral infection caused by cytomegalovirus, as part of complex therapy;

prevention of recurrence of viral infections caused by herpes simplex virus types 1 and 2, Varicella Zoster virus, human papillomavirus, cytomegalovirus;

prevention and treatment of genital warts and cervical pathology caused by human papillomavirus, cytomegalovirus;

prevention and treatment of conditions accompanied by a decrease in local immunity, incl. nonspecific vulvovaginitis, vulvovaginal candidiasis and bacterial vaginosis, as part of complex therapy;

symptoms of discomfort in the genital area, accompanied by itching, burning and dryness, incl. after intercourse;

the phenomenon of discomfort in the genital area, accompanied by itching, burning and dryness of the mucous membranes, with insufficient ovarian function.

Outwardly, intravaginally, intraurethrally.

Shake the can before use. Keep the balloon in an upright position during use. When applied externally, the drug is applied to the entire affected skin surface from a distance of 4Ц5 cm by 1Ц2 valve presses, which is the optimal therapeutic dose.

For intravaginal use of the drug, a special nozzle with a spray is attached. Remove the valve from the spray bottle and put on the nozzle valve. Then insert the nozzle into the vagina and inject by 1-2 clicks of the nozzle, which is the optimal therapeutic dose.

When used by men, in addition to external application, the drug is injected into the external opening of the urethra by 1-2 pressing of the spray valve.

In case of herpesvirus infection type 1, shingles, the drug is recommended to be used 6 times a day, on the lesion, for 5 days. With a persistent course of the infectious process, the period of treatment is extended until the symptoms of the disease completely disappear.

In case of herpesvirus infection type 2 (genital herpes), CMV infection is recommended to be applied 5 times a day for 14 days externally and intravaginally, after stopping the relapse - externally and intravaginally 3 times a day for 10 days.

In order to prevent recurrence of genital herpes and CMV infection, the drug is recommended to be used externally and intravaginally from the 18th to 20th day of the menstrual cycle until the end of menstruation, 2 times a day, in the morning and in the evening.

In case of human papillomavirus infection, the drug is recommended to be used:

- before removal of genital warts - 3 times a day during the entire period of etiotropic therapy;

- against the background of destruction - 5 times a day for 10 days or more until complete healing;

- for the prevention of immediate relapses 3 times a day for 1 month.

To prevent the progression of papillomavirus infection, it is recommended to use it before and after intercourse, as well as in the event of provoking factors (stress, overwork, respiratory viral infections, microflora disturbance, taking antibiotics, cytostatics) - 3 times a day intravaginally and externally during the entire period of exposure to provoking factors.

For bacterial vaginosis, nonspecific vulvovaginitis and vulvovaginal candidiasis, the drug is recommended to be used intravaginally 3-4 times a day for 7-10 days. If necessary, repeat the course of treatment after 10 days. In the event of provoking factors (respiratory viral infections, taking antibiotics, cytostatics) - intravaginally and externally 3 times a day during the entire period of exposure to provoking factors.

In case of symptoms of discomfort in the genital area, accompanied by itching, burning and dryness of the mucous membranes - 2 times a day (morning and evening) for 2-3 weeks. In order to prevent conditions of discomfort, apply regularly after intercourse.

As a prophylactic antiviral agent, the drug is recommended to be used before and after intercourse.

Hypersensitivity to the components of the drug.

pharmachologic effect

Antiviral agent for external and local use. Glycyrrhizic acid is active against DNA and RNA viruses, including various strains of viruses Herpes simplex, Varicella zoster, human papillomaviruses, cytomegaloviruses. The antiviral effect is apparently associated with the induction of the formation of interferon. It interrupts the replication of viruses in the early stages, causes the release of the virion from the capsid, thereby preventing its penetration into cells. This is due to the selective dose-dependent inhibition of phosphorylating kinase P. Interacts with the structures of the virus, changing various phases of the viral cycle, which is accompanied by irreversible inactivation of viral particles (in a free state outside the cells), blocking the introduction of active viral particles through the cell membrane into the cell,and also a violation of the ability of viruses to synthesize new structural components. Inhibits viruses at concentrations that are non-toxic to normally functioning cells. Virus strains resistant to acyclovir and iodouridine are highly sensitive to glycyrrhizic acid. It also has an anti-inflammatory, analgesic and tissue regeneration effect both in the early manifestations of a viral infection and in ulcerative forms.

Side effect

Rarely: allergic reactions.

Application during pregnancy and lactation

Application during pregnancy and lactation is possible for absolute indications. In experimental studies, the embryotoxic and teratogenic effects of glycyrrhizic acid have not been established.

special instructions

In the treatment of skin infections caused by the Varicella zoster virus, external use of glycyrrhizic acid should be combined with the ingestion of specific antiviral drugs. During the period of treatment, it is not recommended to use inducers of interferon synthesis. If signs of irritation of the skin or mucous membranes appear, treatment should be discontinued.

Drug interactions

With the simultaneous use of glycyrrhizic acid with other antiviral drugs (acyclovir, iodouridine, interferon), potentiation of the antiviral action is noted.